Software

Certara offers predictive science and informatics solutions that enable cross-disciplinary and translational approaches to drug development.

PBPK Modeling and Simulation

Simcyp is now part of Certara, continues delivering leading-edge science, accelerating drug discovery and development for its Consortium of member pharma companies. More about Simcyp on simcyp.com

Simcyp Population-based Simulator Predict drug absorption and disposition in virtual patient populations, including paediatrics. Learn more at simcyp.com

Consultancy for a broad spectrum of DMPK issues, including optimal design for metabolic drug-drug interaction studies, interpretation of data and prediction of in vivo ADME from in vitro studies Learn more at simcyp.com

Interactive workshops and courses cover the concepts of model-based drug development with focus on incorporating population variability into mechanistic prediction of PK and modelling of PK-PD Explore upcoming events at simcyp.com

Key Publications Simcyp actively publishes the results of its research in the form of conference abstracts and peer-reviewed papers. Explore citations and published articles

Bookmark and Share

Simcyp Animal

Simcyp has developed a whole-body physiologically-based pharmacokinetic (PBPK) modelling platform for rat, dog and knock-out mouse which can be used to:

  • assess PK properties
  • evaluate formulation and food effects on drug absorption
  • predict concentration-time profiles in plasma, tissues and organs 
  • investigate the formation and kinetics of primary metabolites.

Simulations with Simcyp Animal can help in the identification of key data requirements and the design of subsequent experiments and have been used to increase confidence in in vitro – in vivo extrapolation (IVIVE) before moving to human simulations.

When used in conjunction with the Simcyp Population-based Simulator, Simcyp Animal allows comparison of human and animal data without relying upon allometric scaling, which may not be a valid approach for some parameters.